From in vivo to in vitro: The medical device testing paradigm shift
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Amid growing efforts to advance the replacement, reduction, and refinement of the use of animals in research, there is a growing recognition that in vitro testing of medical devices can be more effective, both in terms of cost and time, and also more reliable than in vivo testing. Although the technological landscape has evolved rapidly in support of these concepts, regulatory acceptance of alternative testing methods has not kept pace. Despite the acceptance by regulators of some in vitro tests (cytotoxicity, gene toxicity, and some hemocompatibility assays), many toxicity tests still rely on animals (irritation, sensitization, acute toxicity, reproductive/developmental toxicity), even where other industrial sectors have already abandoned them. Bringing about change will require a paradigm shift in current approaches to testing - and a concerted effort to generate better data on risks to human health from exposure to leachable chemicals from medical devices, and to boost confidence in the use of alternative methods to test devices. To help advance these ideas, stir debate about best practices, and coalesce around a roadmap forward, the JHU-Center for Alternatives to Animal Testing (CAAT) hosted a symposium believed to be the first gathering dedicated to the topic of in vitro testing of medical devices. Industry representatives, academics, and regulators in attendance presented evidence to support the unique strengths and challenges associated with the approaches currently in use as well as new methods under development, and drew next steps to push the field forward from their presentations and discussion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250 · cited 1×
“Dongeun Huh and Donald Ingber largely developed the initial proof-of-concept of this organ-on-chip technology (Huh et al., 2010).”
BackgroundOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185 · cited 1×
“Given the tremendous costs of drug development and the long timelines involved, major pharmaceutical companies and government agencies are expressing particular interest in the organ-on-a-chip models (Esch et al., 2015).”
BackgroundOops they did it again! Carbon nanotubes hoax scientists in viability assays
Wörle-Knirsch, J. M., Pulskamp, K., & Krug, H. F. (2006) · Nano Letters · doi:10.1021/nl060177c · Cited by 994
Marx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295 · cited 5×
“A strategy needs to be developed on how standardized inhalation tests can be performed with 3D in vitro test systems (Alépée et al., 2014; Gordon et al., 2015; Marx et al., 2016) to demonstrate the feasibility of combining TTC with upcoming technologies.”
BackgroundInfluentialAlternative in vitro assays in nanomaterial toxicology
Hartung, T., & Sabbioni, E. (2011) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.153 · Cited by 84 · cited 3×
“Thus, there are unique challenges in working with nanomaterials in in vitro tests (Hartung, 2010; Hartung and Sabbioni, 2011) – and the use and testing of medical devices containing nanomaterials must be approached with caution (Silbergeld et al., 2011).”
BackgroundMethodSelf-citationElliott, J. (2017) · ALTEX · doi:10.14573/altex.1605021 · Cited by 84
Use of cause-and-effect analysis to design a high-quality nanocytotoxicology assay
Rösslein, M., Elliott, J. T., Salit, M., Petersen, E. J., Hirsch, C., Krug, H. F., & Wick, P. (2015) · Chemical Research in Toxicology · doi:10.1021/tx500327y · Cited by 81
Self-citationNanomaterial Cell Interactions: Are Current In Vitro Tests Reliable?
Hirsch, C., Roesslein, M., Krug, H. F., & Wick, P. (2011) · Nanomedicine · doi:10.2217/nnm.11.88 · Cited by 71
Self-citation
Cited by
Design of biodegradable, implantable devices towards clinical translation
Li, C., Guo, C., Fitzpatrick, V., Ibrahim, A., Zwierstra, M. J., Hanna, P., Lechtig, A., Nazarian, A., Lin, S. J., & Kaplan, D. L. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0150-z · Cited by 808
In vitro neurons learn and exhibit sentience when embodied in a simulated game-world
Kagan, B. J., Kitchen, A. C., Tran, N. T., Habibollahi, F., Khajehnejad, M., Parker, B. J., Bhat, A., Rollo, B., Razi, A., & Friston, K. J. (2022) · Neuron · doi:10.1016/j.neuron.2022.09.001 · Cited by 400
Advances in acute toxicity testing: strengths, weaknesses and regulatory acceptance
Erhirhie, E. O., Ihekwereme, C. P., & Ilodigwe, E. E. (2018) · Interdisciplinary Toxicology · doi:10.2478/intox-2018-0001 · Cited by 329
Animal testing and its alternatives—the most important omics is economics
Meigs, L. (2018) · ALTEX · doi:10.14573/altex.1807041 · Cited by 184
Silva, R. J., & Tamburic, S. (2022) · Cosmetics · doi:10.3390/cosmetics9050090 · Cited by 63
“The usage of ‘organ-on-chip’ systems seeded with human cells may be a viable substitute to in vivo tests in the future [91].”
Background
Metadata
- Authors
- Myers, D.
- Venue
- ALTEX
- Publisher
- ALTEX Edition
- Published
- 2017
- Volume
- 34
- Issue
- 4
- Pages
- 479-500
- ISSN
- 0946-7785 (ISSN-L)
- 1868-596X
- OpenAlex
- W2617289704
- Cited by
- 66
- References
- 8
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.